History of the DCP Program

In 2017 in cooperation with the SGC Frankfurt the pharmaceutical companies AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer and Takeda initiated the DCP project. They agreed to make an initial set of 70 high-quality chemical probes available to the public, including their characterisation data, control compounds with similar structure scaffold and recommendations on use. The selectivity of most compounds was further assessed in a GPCR and KinomeScan. Some compounds required" additional characterisation that was carried out by the SGC in house or with the support of the Division of Pre-Clinical Innovation of the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program housed at the laboratory of Dr Bryan Roth at UNC. All data as well as the physical compounds were made accessible to the research community.

This website was launched in March 2018.

Later on academic groups started to donate probes. The number of donators is growing and the program has well succeeded the initial goal of 70 probes.